Delivery Order SPE2DB24D3013-SPE2DB25FFPEL
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for DUPIXENT 300 MG/2 ML pen injections with a ceiling value of $4,147.68 under a firm fixed price contract type. The award was made on September 3, 2025, with an ultimate completion date of September 4, 2025, with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform this work at its corporate office location. This delivery order represents a child...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,747.93 to AmerisourceBergen Drug Corp for the supply of DUPIXENT 300 mg/2 mL pen injectors. The contract is a firm fixed-price delivery order with an ultimate completion date of September 3, 2025, and represents a non-set-aside competitive award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform at its corporate office location. This delivery order falls under the company's broader...
- The Defense Logistics Agency awarded a $4,929.52 delivery order to AmerisourceBergen Drug Corp for DUPIXENT (dupilumab) 300 mg/2 mL pen injections on June 18, 2025, with an ultimate completion date of June 20, 2025. This non-competitive, firm fixed-price delivery order represents a continuation of pharmaceutical supply under AmerisourceBergen's existing contract vehicle with DLA. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded a delivery order valued at $6,819.43 to AmerisourceBergen Drug Corp for the supply of DUPIXENT 200 MG/1.14 ML pen injectors on August 6, 2025, with completion expected by August 7, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. DUPIXENT (dupilumab) is a prescription biologic medication used to treat various...
- The Defense Logistics Agency awarded a delivery order valued at $12,879.52 to AmerisourceBergen Drug Corp for DUPIXENT 300 MG/2 ML pen auto-injectors on August 8, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through December 2026. The place of performance is listed as Conshohocken, Pennsylvania, where AmerisourceBergen maintains its...
- The Defense Logistics Agency awarded a delivery order valued at $8,632.83 to AmerisourceBergen Drug Corp for DUPIXENT 300 MG/2 ML pen injectors (2ML). The contract, executed on August 28, 2025, with completion targeted for August 29, 2025, represents a firm fixed-price delivery order with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, fulfilled this order through competitive procurement processes. This...
- The Defense Logistics Agency awarded a delivery order valued at $48,006.54 to AmerisourceBergen Drug Corp for DUPIXENT 300 mg/2 mL pens on August 14, 2025, with an ultimate completion date of August 15, 2025. The contract is structured as a firm fixed-price delivery order with no set-aside designation, indicating the award was competitively procured. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for DUPIXENT 300 MG/2 ML pen injectors valued at $7,550.30 under a firm fixed price contract. The award was made on July 21, 2025, with an ultimate completion date of July 22, 2025, and represents a non-set-aside competitive award. AmerisourceBergen will perform this work at its corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a $6,995.86 delivery order to AmerisourceBergen Drug Corp on September 18, 2025, for the supply of DUPIXENT 300 MG/2 ML pen injectors (2 ML). This is a firm fixed price, non-set-aside contract with an ultimate completion date of September 19, 2025, and performance to be executed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency awarded a $39.7K delivery order to AmerisourceBergen Drug Corp for DUPIXENT (dupilumab) 300 mg/2 mL pen injectors on August 19, 2025, with an ultimate completion date of August 20, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. The delivery will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger...
- SPE2DB24D3013Indefinite Delivery Contract
- SPE2DB24D3013-SPE2DB25FFPELDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $3,523.82 to AmerisourceBergen Drug Corp for DUPIXENT (dupilumab) 300 mg/2 mL pen injections on August 8, 2025, with an ultimate completion date of August 11, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.999 billion global pharmaceutical support vehicle running through December 2026. The work will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, serves as a critical vendor for federal medical procurement through the DLA Medical Supply Chain. The company supplies a comprehensive range of pharmaceutical products including specialty medications, brand-name and generic drugs, vaccines, and medical devices to support military healthcare programs worldwide. This delivery order for DUPIXENT, a biologic treatment used for conditions such as atopic dermatitis and eosinophilic asthma, supports the Defense Health Agency and other federal healthcare systems through the flexible and comprehensive pharmaceutical prime vendor contract structure.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.5k | 8/8/25 |